Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the publication of the RAPID C-19 Oversight Group report on 6 October, whether the Antivirals and Therapeutics Taskforce has determined the nature and threshold of evidence required for a prophylactic monoclonal antibody treatment to be made available via interim clinical policy before an appraisal by the National Institute for Health and Care Excellence.

The interim procurement decisions on COVID-19 treatments, including prophylactics, have been based on the available evidence of clinical effectiveness and advice from expert groups, including RAPID C-19 and a United Kingdom national expert policy working group. This considers the available clinical evidence for efficacy in preventing symptomatic infection, hospitalisation or mortality from COVID-19. Any future decisions on licensed treatments in England, including prophylactics, will be taken through the National Institute for Health and Care Excellence’s health technology evaluation process.